Efficacy and Safety of Crisaborole by Body Region in Infants with Mild-to-moderate Atopic Dermatitis

Douglass W. Forsha,Joel Schlessinger,Julie S. Shepard,John L. Werth,Chuanbo Zang,Amy Cha,Liza Takiya

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY（2022）

引用 0|浏览10

暂无评分

摘要

Background: Crisaborole ointment, 2%, is a nonsteroidal anti-inflammatory phosphodiesterase 4 inhibitor for treatment of mild-to-moderate atopic dermatitis (AD). This post hoc analysis of the phase 4, open-label, single-arm, 28-day study CrisADe CARE 1 (NCT03356977) examined the efficacy and safety of crisaborole by body region in infants.

查看译文

关键词

crisaborole,mild-to-moderate

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要